Clinical Trial Update: Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury

View source ↗

Summary

A completed clinical trial evaluating neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for early and evolving acute kidney injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Snippet

Sponsor: Abbott RDx Cardiometabolic | Conditions: Kidney Failure, Acute | Status: COMPLETED